Answers are grounded in this paper and cite their sources.
Retrospective study uncovers distinct immunophenotypic, genetic, and survival profiles between primary effusion lymphoma and fluid overload large B-cell lymphoma, indicating divergent pathogenesis.
Primary effusion lymphoma (PEL) and fluid overload-associated large B-cell lymphoma (FO-LBCL) are rare B-cell neoplasms presenting as serous effusions without solid masses, distinguished primarily by human herpesvirus-8 status. We analyzed three PEL and seven FO-LBCL cases using immunohistochemistry, Epstein-Barr virus-encoded RNA in situ hybridization, immunoglobulin heavy chain (IGH), T-cell receptor beta (TRB) and T-cell receptor gamma (TRG) gene rearrangement analyses, and targeted next-generation sequencing. The median age was 72 years for PEL and 83 years for FO-LBCL. All PEL cases lacked CD20, whereas FO-LBCL tumors retained pan-B-cell markers. Aberrant T-cell antigen expression was observed in two PEL cases, both showing clonal T-cell receptor rearrangements in addition to IGH clonality. FO-LBCL harbored recurrent alterations involving CD79B, PIM1, and MYD88, suggesting partial molecular overlap with the molecular features characteristic of the MCD subtype of diffuse large B-cell lymphoma (DLBCL). Clinically, all patients with PEL died of disease, whereas FO-LBCL appeared to have a more favorable clinical course, with four patients remaining alive at the last follow-up. Despite morphologic overlap, PEL and FO-LBCL showed distinct immunophenotypic, genetic, and clinical features. These preliminary findings support further investigation of B-cell receptor/NF-κB-related signaling pathways in FO-LBCL and may contribute to improved molecular classification and future therapeutic stratification.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: